ClinicalTrials.gg
Active, not recruitingNCT04677790TETI-IIUpdated Mar 11, 2026

Gradual Egg-tolerance Induction in Hen's Egg Allergic Children Who Tolerate Baked Egg (TETI-II Study)

An interventional study of assigned period of specific dietary restrictions in Egg Hypersensitivity, sponsored by Dominque Bullens. Active, not recruiting at 4 sites in Belgium. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Dominque Bullens · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
12 Months to 18 Years
Sex
All
01

Study summary

The investigators want to test the hypothesis that a total period of 12 months of stepwise open egg introduction is not inferior when compared to a total period of 20 months gradual open egg introduction of a certain egg product with regard to full egg tolerance induction.

Read the detailed description
  1. The investigators want to test the hypothesis that a total period of 12 months of stepwise open egg introduction is not inferior when compared to a total period of 20 months gradual open egg introduction of a certain egg product (see steps for the specific egg products) with regard to full egg tolerance induction.

    Step 1: open baked egg test passed (either at home or in the hospital): this is routine clinical practice; afterwards daily intake of increasing amounts of heated egg (amounts to be noted in diary)

    Step 2: open provocation test at home with 10 minutes hard-boiled egg, both hen's egg white and yolk, passed; afterwards weekly intake of either hard-boiled egg white or yolk or both (amounts and days to be noted in diary)

    Step 3: open provocation test at home with omelet, pancake or scrambled egg passed; afterwards weekly or two-weekly intake of one of these specific preparation forms or of the previous preparation forms (amounts, days and preparation to be noted in diary)

    Step 4: open provocation test at home with 4 minutes fried or poached egg or softly boiled egg with liquid yolk; afterwards regular intake of one of these preparation forms or one of the prior steps (amounts, days and preparation to be noted in diary)

    Step 5: open provocation test at home with "raw" egg: eg. In chocolate mousse; mayonnaise or tiramisu; afterwards unlimited intake of all egg containing preparation forms (for 3 months in both groups to be noted in the diary)

    If tolerance to a certain step is not yet present (this is: if any reaction occurred during the months registered between two steps), the next step will be postponed with the length of the previous step. The number of failures (any reaction in relation to egg ingestion), the type of reaction and the additional time period necessary before the next step can be taken, will be recorded.

  2. The investigators will also study the time to complete tolerance in the complete cohort (this is the time to complete step 1 to step 5).
  3. Furthermore, the investigators want to study the induction of IL-10-producing ICOS-expressing hen's egg specific Treg cells in vitro paralleling tolerance induction.
  4. The investigators also want to study whether we can correlate the results of the in-house developed in vitro BAT with different heated hen's egg ingredients to the results of the egg provocation test and whether BAT could substitute for egg OFC tests for the different steps in the future.
02

Conditions studied

  • Egg Hypersensitivity

Browse trials for

03

In context

Egg Hypersensitivity

38 studies on the registry are indexed under Egg Hypersensitivity; 9 are open to participants now.

This study's planned enrollment of 62 is below the median of 73 across 27 interventional studies indexed under Egg Hypersensitivity.

Browse Egg Hypersensitivity studies →

Lead sponsor

Dominque Bullens is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children (1-18y) had or have a clinical diagnosis of IgE mediated hen's egg allergy based on positive history as well as skin prick testing and/or specific IgE detection by CAPtest in an allergy clinic
  2. Children are at least 12 months old before introduction of heated egg is considered
  3. Children did not suffer from grade 4 anaphylaxis due to egg-ingestion at presentation (for grade 4 anaphylaxis, see EAACI anaphylaxis guidelines, Muraro A et al, Allergy. 2014 Aug;69(8):1008-25).
  4. Children have specific IgE levels to Gal d 1 below 1.2 kU/mL (12-24 months) or below 5 kU/mL (>24 months) or have a level that predicts a good chance (>75%) to pass the baked egg provocation test by cake (see Bartnikas LM et al, J Allergy Clin Immunol Pract 2013; 1: 354-360) and/or children passed baked egg provocation test by cake executed on clinical judgement.

Exclusion criteria

Exclusion Criteria:

  1. Children had grade 4 anaphylaxis (for grade 4 anaphylaxis, see EAACI anaphylaxis guidelines, Muraro A et al, Allergy. 2014 Aug;69(8):1008-25) due to egg ingestion
  2. Children are younger than 12 months old at the moment of passing cake open provocation test
  3. Parents are not able or not willing to adhere to a certain egg step-containing diet on a regular basis at home
  4. Parents and/or children are not willing to give IC/assent
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Active comparator
    "Very short arm" (12 months)

    Very short arm (12 months): 3 months between every step. Step by step gradual introduction of egg containing food products during 12 months, unless next step can not be taken.

    Behavioral: assigned period of specific dietary restrictions

  • Active comparator
    "Short arm" (20 months)

    Short arm (20 months): 5 months between every step. Step by step gradual introduction of egg containing food products during 20 months, unless next step can not be taken.

    Behavioral: assigned period of specific dietary restrictions

Interventions

  • Behavioralassigned period of specific dietary restrictions

    Step by step gradual introduction of egg containing food products

06

What researchers measure

Primary outcomes

  1. Time to complete egg tolerance

    The proportion of children in each group evolving from step 1 to step 5 within the anticipated time period (12 versus 20 months), followed by 3 versus 5 months of uneventful liberal egg intake for observation after step 5.

    Time frame: 12 to 20 months

Secondary outcomes

  1. The proportion of children evolving from any step to the next step within anticipated time period

    The proportion of children evolving from any step to the next step within anticipated time period

    Time frame: 3 to 5 months

  2. Influence of age at inclusion in relation to the proportion of failures

    Influence of age at inclusion in relation to the proportion of failures

    Time frame: 12 to 20 months

  3. Influence of specific IgE of hen's egg and/or components in relation to the proportion of failures

    Influence of specific IgE of hen's egg and/or components in relation to the proportion of failures

    Time frame: 12 to 20 months

  4. Influence of the dietary intake of the specific egg-containing products in relation to the proportion of failures

    Influence of the dietary intake of the specific egg-containing products (in number of times a week and in portion) in relation to the proportion of failures

    Time frame: 12 to 20 months

  5. Induction of Treg over time in parallel to gradual complete hen's egg tolerance induction.

    We will study the difference in ICOS-expression as well as IL-10/IL-5 \& IL-10/IL-4 ratio at enrollment between healthy and egg-allergic children

    Time frame: 12 to 20 months

  6. Can in vitro BAT for a certain step predict tolerance?

    Do the results of the BAT with different heated hen's egg ingredients correlate with the egg intake at home?

    Time frame: 12 to 20 months

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No — Data will be analysed and grouped before release

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Jul 2025, 54 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2020
First posted
Dec 21, 2020
StartActual
Dec 9, 2020
Primary completionActual
Jul 2, 2025
CompletionEst.
Jul 2026
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04677790
Lead sponsor
Dominque Bullens
Collaborators
Imelda Hospital, Bonheiden, AZ Sint-Jan AV
Responsible party
Dominque Bullens (Clinical Professor, Universitaire Ziekenhuizen KU Leuven) — Sponsor-investigator
First posted
Dec 21, 2020
Start date
Dec 9, 2020
Primary completion
Jul 2, 2025
Completion
Jul 2026 (estimated)
Last update
Mar 11, 2026

Study contacts

Dominique Bullens, MD, PhD
principal investigator · Universitaire Ziekenhuizen KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion